Please select the option that best describes you:
Topics:
Breast Cancer • Radiation Oncology • Medical Oncology • NCI-CCC Tumor Board Question • University of Wisconsin • HR+ • NCI-CCC Breast Tumor Board Question
Would you offer definitive local therapy to a patient with ER/PR+, Her2 neg breast cancer with oligometastatic disease that responded well to CDK 4/6 inhibitor +AI, despite NRG-BR002 results?
Young healthy patient, ER/PR positive HER2 negative right breast cancer with a synchronous single site of oligometastatic disease in the right 4th rib (near primary tumor but not clearly direct extension) and good response to 6 months of AI+CDK4i
Answer from: Radiation Oncologist at Community Practice
Agree with @Amye Tevaarwerk, we approach in the same manner in ER+/HER2- breast patients with favorable response on systemic therapy -- don't offer SBRT with good response on systemic therapy.
In the setting of true oligoprogression in ER+/HER2- tumors at primary site or at known met while on...
Comments
Medical Oncologist at MedStar Washington Hospital Center, MedStar Georgetown University Hospital
Dr. @Arscott, Would this be your approach for a p...
Dr. @Arscott, Would this be your approach for a p...
Radiation Oncologist at Compass Oncology
If enhancement properties and peritumoral edema/T2...
If enhancement properties and peritumoral edema/T2...
See also recent updates to relevant discussion fro...